why choose us

First received: May 11, 2023

Clinical Trial: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Lymphoma

Study Type: INTERVENTIONAL


Official Title: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Brief Summary: The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Read more